Select the name of the type of clinical care program you would like more information about …

Example: ‘B’ for Bladder Cancer

Cancer Treatment A-Z

Skip to content. | Skip to navigation

Personal tools

Navigation

You are here: Home
20 items matching your search terms.
Filter the results.
Item type














New items since



Sort by relevance · date (newest first) · alphabetically
Amos discusses breast cancer in the black community on Black Issues Forum
by William Shawn Davis published Oct 29, 2012 last modified Oct 29, 2012 09:20 AM — filed under: ,
Keith Amos, MD, FACS, was interviewed by UNC-TV’s Black Issues Forum on community education about breast cancer in the African American community on Sunday, Oct. 28.
Located in News / 2012 News
Amos quoted in ABC News feature
by Mary Ruth published Jul 13, 2012 last modified Jul 13, 2012 10:55 AM — filed under: , ,
Keith Amos, MD, assistant professor of surgery at UNC-Chapel Hill, is quoted in an ABC News feature discussing a new study about partial breast removal surgery to treat cancer.
Located in News / 2012 News
Causes of African-American breast cancer incidence study receives $19.3M: UNC partners to form largest US database
by Mary Ruth published Aug 29, 2011 last modified Sep 02, 2011 12:28 PM — filed under: , , ,
Chapel Hill - UNC scientist Robert Millikan will partner with Christine Ambrosone, of Roswell Park Cancer Institute, and Julie R. Palmer, of Boston University, in the most ambitious study to date of breast cancer among younger African-American women.
Located in News / 2011 News
Combination therapy for triple-negative breast cancer disappointing
by Mary Ruth published Jun 12, 2012 last modified Jun 12, 2012 09:31 AM — filed under: , ,
CHAPEL HILL, N.C. – A recent clinical trial testing a combination therapy for basal-like (also known as triple-negative) breast cancer demonstrates that a combination of two drugs with promising preclinical results is not as effective as researchers had hoped.
Located in News / 2012 News
Common transplant drug inhibits breast cancer growth, UNC laboratory study shows
by Mary Ruth published May 26, 2011 last modified May 27, 2011 03:59 PM — filed under: , , , ,
Chapel Hill - Tacrolimus, a drug that is commonly used to prevent organ transplantation rejection, inhibits breast cancer growth in pre-clinical studies. The finding from UNC scientists was reported in the May 26th Public Library of Science.
Located in News / 2011 News
Dr. Lisa Carey authors editorial on neoadjuvant trials for breast cancer
by Mary Ruth published Jun 15, 2012 last modified Jun 22, 2012 02:45 PM — filed under: , ,
Lisa Carey, MD, authored an editorial, titled “Neoadjuvant Trials of Human Epidermal Growth Factor Receptor 2 Targeting: How Many Drugs Do We Need?”
Located in News / 2012 News
Editorial urges rapid clinical trials for targeted breast cancer therapies
by Mary Ruth published Dec 20, 2011 last modified Dec 20, 2011 09:07 AM — filed under: , ,
Chapel Hill, NC – In an editorial published today in the Journal of Clinical Oncology, UNC associate professor E. Claire Dees, MD, reviews current evidence on the safety and efficacy of combination therapies currently used for metastatic breast cancer and urges clinical researchers to move forward with new studies that leverage advances in the identification of tumor biomarkers.
Located in News / 2011 News
Exercise, even mild physical activity, may reduce breast cancer risk
by Mary Ruth published Jun 25, 2012 last modified Jun 25, 2012 03:31 PM — filed under: , ,
A new analysis done by University of North Carolina at Chapel Hill researchers has found that physical activity - either mild or intense and before or after menopause - may reduce breast cancer risk, but substantial weight gain may negate these benefits.
Located in News / 2012 News
Grant to fund use of kinase test in HER2-positive breast cancer
by Mary Ruth published May 14, 2012 last modified May 15, 2012 03:49 PM — filed under: , ,
Chapel Hill, NC – Susan G. Komen for the Cure® has awarded a grant of almost $900,000 to Lisa A. Carey, MD, and Gary Johnson, PhD, to research clinical applications for the first broad-based test for protein kinase activation and response to inhibitory drugs in HER2-positive breast cancer.
Located in News / 2012 News
Parise and Leisner research into protein CIB1 profiled in Raleigh News and Observer
by William Shawn Davis published Oct 29, 2012 — filed under: ,
The Raleigh News and Observer interviewed Leslie Parise, PhD, professor and chair of the department of biochemistry, and Tina Leisner, PhD, a UNC research associate in biochemistry, about their research into the linkage between breast cancer and the protein CIB1.
Located in News / 2012 News